











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































All	 results	 are	 presented	 as	 the	mean	 +/-	 standard	 error	 of	 the	mean.	 For	 determination	 of	




































































































































































































































































































































































































































































































































































































































To	 confirm	 ROS	 generation	 following	 glutamine	 deprivation,	 MitoSOX	 Red	 dye	 was	 used	 to	
quantify	 mitochondrial	 ROS	 and	 assessed	 via	 flow	 cytometry	 as	 detailed	 by	 Pacher	 and	
colleagues(29).		
Statistical	analysis	
All	 results	 are	 presented	 as	 the	mean	 +/-	 standard	 error	 of	 the	mean.	 For	 determination	 of	
statistical	 significance,	 data	 were	 analyzed	 by	 ANOVA,	 and	 significant	 differences	 between	
various	 treatment	 groups	were	assessed	via	 student’s	 t-test	 (P	 =	 0.05).	 Each	experiment	was	
independently	repeated	at	least	three	times.	
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4.3	Results		
4.3.1	RAS-transformed	tumor	cells	require	glutamine	for	mitochondrial	matrix	redox	poise			
Previous	studies	of	oncogenic	glutaminolysis	have	demonstrated	that	glutamine	exerts	
antioxidant	effects,	as	demonstrated	by	an	increase	in	ROS	following	glutamine	deprivation	or	
disruption	of	glutaminolysis(4,	7,	9,	30).	To	further	understand	glutamine’s	role	in	redox	
homeostasis,	and	to	determine	whether	the	need	for	glutamine	supplementation	varies	
according	to	transformation	status,	an	isogenic	cell	line	series	was	exposed	to	24h	glutamine	
deprivation.	The	MCF	cell	series	is	built	upon	the	genetic	background	of	MCF10A	cells,	which	
are	non-transformed,	spontaneously	immortalized	breast	epithelial	cells(31).	These	cells	were	
experimentally	transformed	with	T-24	HRAS	to	form	the	MCF10AT	cell	line(31,	32).	In	separate	
efforts,	two	other	cells	lines	of	advanced	malignancy,	MCF10ADCIS.com	(herein	referred	to	as	
MCFDCIS)	and	MCFCA1D,	were	formed	from	xenografts	of	MCF10AT(33,	34).	The	MCF	cell	
series	is	particularly	useful,	because	it	has	representative	stages	of	cancer	progression.	Cells	
vary	with	respect	to	oncogenic	RAS	activation	(MCF10Awt,	nontransformed),	tumorigenesis	
(MCFDCIST24	HRAS,	tumorigenic/non-metastatic),	and	metastatic	capability	(MCFCA1DT24	HRAS,	
tumorigenic/metastatic)	(Figure	4.1)(31-35).		
To	monitor	subcellular	glutathione	redox	responses	to	glutamine	deprivation,	all	cell	lines	
were	stably	transfected	with	the	cytosolic	and	mitochondrial	matrix-targeted	Grx1-roGFP2	
biosensors.	All	results	are	reported	as	percent	oxidation	of	the	glutathione	biosensor	and	
should	be	compared	to	baseline	redox	potential,	which	uniquely	varies	amongst	cell	types.	As	
seen	in	our	investigation,	as	well	as	in	the	investigations	of	others,	the	cytosolic	biosensor	is	
significantly	more	reduced	at	baseline	in	all	cells(20,	26).	
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The	isogenic	MCF10A/DCIS/CA1D	series	varied	in	glutathione	redox	response	to	24h	
glutamine	deprivation	(Figure	4.2).	The	HRAS-transformed	DCIS	and	CA1D	cell	lines	required	
glutamine	to	maintain	mitochondrial	matrix	glutathione	redox	poise,	whereas	the	non-
transformed	MCF10A	cells	did	not	(Figure	4.2A).	MCFDCIS	and	CA1D	cells	underwent	
statistically	significant	oxidation	of	9.8%	and	11.5%,	respectively,	and	the	non-transformed	
parental	MCF10A	cells	underwent	a	small,	non-statistically	significant	4.2%	oxidation.	Two	
KRAS-transformed	cells	lines—A549	lung	adenocarcinoma	and	MiaPaCa-2	pancreatic	
carcinoma—showed	similar	oxidative	responses	to	24h	glutamine	deprivation.	MiaPaCa-2	
underwent	an	8.4%	oxidation,	and	A549	cells	responded	most	strongly	by	undergoing	an	18.7%	
oxidation	(Figure	4.2A).		
Cytosolic	redox	responses	to	glutamine	deprivation	were	also	monitored	in	response	to	24h	
glutamine	deprivation	(Figure	4.2B).	Recently,	a	“non-canonical”	pathway	of	glutamine	
utilization	in	RAS-transformed	cells	was	described(9).	In	non-canonical	glutaminolysis,	
mitochondrial	glutamate	engages	the	malate	aspartate	shuttle	to	produce	cytosolic	aspartate	
to	function	in	oxidant	defense	(Figure	4.3)(9).	The	investigators	reported	that	KRAS-
transformed	pancreatic	ductal	adenocarcinoma	cells	preferentially	divert	glutamine-derived	
glutamate	away	from	entering	TCA	cycle	metabolism	via	glutamate	dehydrogenase	and	into	the	
cytosol	to	produce	NADPH	for	glutathione	redox	balance	via	malic	enzyme.	In	keeping	with	this	
model,	we	hypothesized	that	RAS-transformed	cells	would	undergo	cytosolic	glutathione	
oxidation	in	response	to	glutamine	deprivation.	However,	24h	glutamine	deprivation	did	not	
oxidize	cytosolic	glutathione	in	any	cell	type	studied.	Interestingly,	a	slight	but	statistically	
significant	reduction	in	glutathione	redox	was	observed	in	MCF	DCIS	and	CA1D	cells	(Figure	
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4.2B).	These	results	indicate	that	RAS-transformed	cells	require	glutamine	for	the	specific	
preservation	of	mitochondrial	matrix	glutathione	redox	potential.	
Glutamine	is	a	versatile	onconutrient	that	provides	nitrogen	for	amino	acid	and	nucleotide	
biosynthesis,	an	oxidizable	carbon	skeleton	for	energy	and	reducing	equivalent	generation,	and	
glutamate	for	glutathione	biosynthesis(11,	12).	To	further	probe	the	node	of	glutamine	
metabolism	responsible	for	the	preservation	of	mitochondrial	matrix	redox	poise,	cells	were	
supplemented	during	glutamine	deprivation	with	cell-permeable	alpha-ketoglutarate	(α-KG).	
Alpha-ketoglutarate	is	a	TCA	cycle	carbon,	amino	acid	precursor,	and	downstream	metabolite	
of	glutamine.	When	supplemented	with	α-KG	during	glutamine	deprivation,	mitochondrial	
matrix	glutathione	was	less	oxidized	in	all	cells	and	fully	recovered	in	A549	and	MiaPaca-2	cells.	
Thus,	it	is	glutamine’s	5-carbon	backbone	(α-KG)	that	serves	in	mitochondrial	antioxidant	
defense	(Figure	4.2A).		
4.3.2	Glutamine	deprivation	results	in	superoxide	production	and	loss	of	GSH	content		
Oxidation	of	Grx1-roGFP2	could	result	from	changes	in	ROS	production,	upset	of	glutathione	
system	dynamics,	or	both.	Glutamine’s	role	in	preserving	mitochondrial	redox	homeostasis	
could	arise	from	a	number	of	metabolic	pathways(11).	The	two	most	likely	pathways	through	
which	glutamine	provides	redox	balance	are	by	driving	the	production	of	mitochondrial	
reducing	equivalents	in	the	TCA	cycle	and	supplying	the	glutathione	precursor	glutamate.	To	
discern	the	possible	contribution	of	these	mechanisms,	ROS	production	and	glutathione	
content	were	assessed	following	24h	glutamine	deprivation.		
Mitochondrial	superoxide	(O2-•)	production	can	be	quantified	via	the	fluorescent	dye	
MitoSOX	Red,	which	accumulates	in	mitochondria	due	to	its	positive	charge	and	becomes	
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fluorescent	upon	reacting	with	O2-•(36).	Wild	type	A549	cells	were	deprived	of	glutamine	for	
24h	and	stained	with	MitoSOX	Red.	Glutamine-deprived	cells	displayed	a	>33%	increase	in	
superoxide	production	(Figure	4.4).	
	Glutathione	was	quantified	via	monobromobimane	thiol	staining	following	24h	glutamine	
deprivation	(Figure	4.5).	Monobromobimane	(MBB)	is	a	cell	permeable	fluorescent	stain	that	
binds	nonenzymatically	to	sulphydryls	and,	therefore,	can	be	used	to	quantify	shifts	in	
glutathione	content(28).	Cells	of	separate	tissues	have	different	amounts	of	glutathione	and	
thus	raw	(not	background	corrected)	MBB	fluorescence	data	were	normalized	to	control	(full	
medium)	sample	fluorescence	for	each	cell	type.	Wild	type	HRAS-transformed	MCF	DCIS	and	
CA1D	cells	lost	GSH	content	following	24h	glutamine	deprivation;	non-transformed	MCF10A	
cells	did	not.	A	similar	loss	of	GSH	was	observed	in	KRAS-transformed	A549	and	MiaPaCa-2	
cells.	Thus,	mitochondrial	matrix	glutathione	oxidation,	observed	via	mito-Grx1-roGFP2,	
correlates	with	a	loss	of	GSH	during	glutamine	deprivation,	indicating	that	RAS-transformed	
cells	have	an	increased	reliance	on	glutaminolysis	for	glutathione	biosynthesis.		
4.3.3	Alpha-ketoglutarate	supports	GSH	biosynthesis	and	alleviates	mitochondrial	matrix	
oxidation	during	glutamine	deprivation	
Supplemental	α-KG	alleviates	mitochondrial	matrix	glutathione	oxidation	caused	by	glutamine	
deprivation.	To	investigate	this	protective	effect,	mito-Grx1-roGFP2	oxidation	and	cellular	GSH	
content	were	assessed	in	A549	cells	supplemented	with	other	glutaminolytic	carbons	during	
24h	glutamine	deprivation	(Figure	4.6).	Specifically,	contributions	of	the	non-canonical,	
transaminase-driven	pathway	of	glutamine	utilization	to	redox	homeostasis	were	explored	via	
supplementation	with	cell-permeable	aspartate	(dimethyl	aspartate;	Asp),	and	the	contribution	
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of	glutaminolytic	anaplerosis	was	studied	via	supplementation	with	oxaloacetate	(OAA).	GSH	
biosynthesis	was	pharmacologically	inhibited	via	24h	incubation	with	150	µM	BSO.	KRAS-
transformed	A549	cells	were	selected	for	further	study	because	they	responded	the	most	
strongly	to	glutamine	deprivation	and	because	they	are	an	exceedingly	well-studied	cell	line,	
thus	making	the	results	more	generalizable.	Inhibition	of	GSH	biosynthesis	via	BSO	produced	an	
oxidative	response	slightly	less	than	that	observed	during	24h	glutamine	inhibition,	indicating	
that	the	glutathione	oxidation	observed	during	glutamine	deprivation	is	likely	driven	by	both	
enhanced	ROS	production	and	GSH	depletion	(Figure	4.6A).	Supplemental	α-KG	prevented	
mitochondrial	matrix	oxidation	and	significantly	increased	glutathione	content	during	24h	
glutamine	deprivation	(Figure	4.6A	and	B).	Supplemental	aspartate	and	oxaloacetate	did	not	
significantly	increase	GSH	content	or	prevent	the	oxidation	of	mitochondrial	matrix	GSH.		
4.3.4	Mitochondrial	redox	poise	is	dependent	on	glutaminolytic	transamination	
Glutamine	is	first	deaminated	by	glutaminase	to	glutamate	and	is	further	deaminated	by	
mitochondrial	glutamate	dehydrogenase	or	mitochondrial/cytosolic	transaminases	to	yield	α-
KG.	To	investigate	the	glutaminolytic	pathways	responsible	for	the	preservation	of	
mitochondrial	redox	poise,	biosensor-bearing	A549	cells	were	exposed	to	commonly	used	
pharmacologic	inhibitors	of	glutaminolysis:	Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl	
sulfide	(BPTES),	a	glutaminase	inhibitor;	epigallocatechin	gallate	(EGCG),	a	relatively	non-
specific	inhibitor	of	glutamate	dehydrogenase;	and	aminooxyacetic	acid	(AOA),	a	transaminase	
inhibitor	(Figure	4.7)(8,	9,	26).	Cells	were	incubated	for	24h	with	doses	previously	shown	to	
exert	enzyme	inhibition	in	vitro,	and	redox	responses	of	the	cytosolic	and	mitochondrial	matrix	
glutathione	systems	were	monitored	(Figure	4.8).	Metabolic	inhibitor	treatment	did	not	result	
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in	oxidation	of	the	cytosolic	compartment,	consistent	with	cellular	responses	to	glutamine	
deprivation	(Figure	4.8A).	Glutaminase	inhibition	via	50	µM	BPTES	resulted	in	a	small,	non-
significant	oxidation	of	the	mitochondrial	matrix.	Intriguingly,	glutamate	dehydrogenase	
inhibition	via	150	uM	EGCG	resulted	in	a	slight,	significant	reductive	response.	However,	
inhibition	of	transamination	via	1	mM	AOA	resulted	in	robust	oxidation,	on	par	with	total	
glutamine	deprivation	(Figure	4.8B).	Expectedly,	treatment	with	AOA	did	not	potentiate	the	
oxidative	response	due	to	glutamine	deprivation	(data	not	shown).	Furthermore,	inhibiting	
transamination	via	AOA	blocks	the	ability	of	supplemental	α-KG	to	abrogate	mitochondrial	
matrix	oxidation	from	glutamine	deprivation	(Figure	4.9).	These	studies	indicate	that	
glutaminolysis	via	transamination	underlies	glutamine’s	role	in	mitochondrial	matrix	redox	
homeostasis	
4.3.5	Glutaminolysis	is	required	for	growth	in	KRAS-transformed	A549	cells	
To	understand	the	role	of	glutaminolysis	in	tumor	cell	growth,	proliferation	of	wild	type	A549	
cells	was	monitored	over	72h	via	SRB	assay	(Figure	4.10).	In	keeping	with	recent	publications	
outlining	a	KRAS-specific	cell	cycle	checkpoint	that	requires	glutamine	supplementation	to	
provide	nitrogen	for	nucleotide	biosynthesis,	A549	cells	ceased	proliferation	during	glutamine	
deprivation(37-39).	Cell	proliferation	in	glutamine-free	medium	could	not	be	rescued	by	
supplementation	with	α-KG,	Asp,	OAA,	or	all	three	carbons	supplied	together	(Figure	4.10A).	To	
investigate	the	effect	of	oxidative	stress	on	cell	proliferation,	the	antioxidant	n-acetylcysteine	
(NAC)	was	provided.	Antioxidant	NAC	supplementation	increased	the	proliferation	of	cells	in	
complete	medium,	but	could	not	rescue	the	proliferation	of	cells	deprived	of	glutamine	alone	
or	in	combination	with	α-KG	(Figure	4.10B).	Glutaminolytic	inhibitors	had	differential	effects	on	
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A549	cell	proliferation	in	complete	medium	(Figure	4.10C).	Glutamate	dehydrogenase	inhibitor	
EGCG	was	cytotoxic	after	36h	of	exposure.	Glutaminase	inhibitor	BPTES	only	partially	slowed	
cell	growth	over	72h.	Inhibition	of	GSH	biosynthesis	via	BSO	inhibited	proliferation,	but	resulted	
in	no	loss	of	cell	viability.	Similarly,	inhibition	of	transamination	via	AOA	was	not	cytotoxic,	but	
did	halt	cellular	proliferation	similar	to	glutamine	deprivation.	Supplementation	with	α-KG,	a	
product	of	transamination	reactions,	restored	proliferation	of	AOA	treated	cells,	but	to	a	much	
slower	state.	These	data	indicate	that	A549	cells	require	transaminase-mediated	production	of	
α-KG	for	cell	division.		
4.3.6	Glutathione	redox	responses	to	chronic	glutamine	deprivation	
Previous	studies	by	our	laboratory	demonstrate	that	cytosolic	and	mitochondrial	glutathione	
systems	are	independently	maintained	and	that	only	the	mitochondrial	matrix	oxidizes	in	
response	to	24h	disruption	of	GSH	synthesis(26).	To	further	outline	the	need	for	glutamine	in	
preserving	redox	homeostasis,	A549	cells	were	subjected	to	either	chronic	72h	glutamine	
deprivation	or	72h	inhibition	of	GSH	biosynthesis	with	BSO	(Figure	4.11).	Surprisingly,	neither	
treatment	resulted	in	significant	oxidation	of	the	cytosolic	GSH	pool.	The	maintenance	of	
cytosolic	GSH	poise,	despite	chronic	glutamine	deprivation	and	inhibition	of	GSH	biosynthesis,	
highlights	the	importance	A549	cells	place	on	maintaining	the	cytosolic	thiol	redox	state	(Figure	
4.11A).	In	contrast,	the	mitochondrial	matrix	strongly	oxidized	in	response	to	both	treatments	
(Figure	4.11B).	Interestingly,	while	the	oxidation	caused	by	inhibition	of	GSH	synthesis	increases	
over	time,	reaching	drastic	levels	of	oxidation	(>	70%)	by	72h,	the	oxidative	response	resulting	
from	glutamine	deprivation	plateaus	and	does	not	significantly	increase	after	24h.	Thus,	A549	
cells	may	initiate	adaptive	metabolic	responses	to	chronic	glutamine	deprivation.			
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4.4	Discussion		
Glutamine	maintains	mitochondrial	matrix	glutathione	redox	poise		
The	data	herein	demonstrate	that	RAS-transformed	tumor	cells	have	an	increased	need	for	
glutamine	to	maintain	mitochondrial	matrix	redox	homeostasis.	Previous	work	has	detailed	that	
tumor	cells	harboring	oncogenic	MYC	and	RAS	have	an	increased	reliance	on	glutaminolysis	for	
maintenance	of	cellular	homeostasis.	To	outline	glutaminolytic	contributions	to	subcellular	
redox	homeostasis,	the	Grx1-roGFP2	biosensor	was	used	to	survey	cytosolic	and	mitochondrial	
matrix	redox	responses	to	disruptions	in	glutamine	metabolism.	By	specifically	monitoring	real-
time	alterations	in	glutathione	oxidation,	the	Grx1-roGFP2	biosensor	provides	a	unique	tool	
with	which	to	examine	glutamine’s	role	in	subcellular	glutathione	redox	poise.		
Isogenic	cells	of	the	MCF	series,	which	vary	in	RAS	transformation	status	and	malignancy,	
were	exposed	to	24h	glutamine	deprivation.	The	cells	displayed	different	requirements	for	
glutamine	to	maintain	redox	homeostasis.	Neither	cytosolic	nor	mitochondrial	glutathione	
redox	poise	was	significantly	altered	in	MCF10A	cells	following	24h	glutamine	deprivation.	
However,	HRAS-transformed	MCF	DCIS	and	CA1D	cells	underwent	significant	alterations	in	both	
cytosolic	and	mitochondrial	matrix	glutathione	redox	poise.	Mitochondrial	oxidation	was	
similarly	observed	in	KRAS-transformed	A549	and	MiaPaCa-2	cells.	These	data	indicate	that	
RAS-transformed	cells	have	an	increased	reliance	on	glutamine	utilization	for	mitochondrial	
glutathione	redox	homeostasis.	To	our	knowledge,	this	is	the	first	report	of	selective	
mitochondrial	matrix	glutathione	oxidation	in	response	to	disruption	of	glutaminolysis.		
RAS-transformed	cell	lines	significantly	lost	glutathione	content	following	24h	glutamine	
deprivation,	a	response	that	was	not	observed	in	non-transformed	MCF	10A	cells.	Additionally,	
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A549	line	cells	had	increased	mitochondrial	superoxide	production	during	glutamine	
deprivation.	Thus,	the	mechanism	of	mitochondrial	matrix	glutathione	oxidation	by	glutamine	
deprivation	is	multifactorial	and	likely	a	combination	of	decreased	glutathione	content,	
increased	oxidant	production,	and	slowed	oxidative	phosphorylation.		
Links	to	the	metabolic	effects	of	HRAS	transformation	in	the	MCF	cell	series		
Two	past	investigations	comparing	the	metabolic	signatures	of	MCF10A	cells	to	their	HRAS-
transformed	isogenic	counterparts	provide	insight	into	the	RAS-driven	metabolic	differences	
that	underlie	the	differential	responses	of	the	MCF	cell	series	to	glutamine	deprivation.	Smith	
and	colleagues	used	isotope-labeled	[U-13C]-glucose	incorporation	in	MCF10A,	MCF10AT,	and	
MCFCA1A	cells	(a	separate	tumorigenic	cell	line	derived	along	with	the	CA1D	cells)	to	quantify	
relative	fluxes	through	various	metabolic	pathways(13).	Although	transformed	cells	exhibited	
faster	growth	rates	and	had	higher	glucose	uptake	rates,	MCF10A	cells	had	a	higher	glycolytic	
flux	that	resulted	in	≈	98%	of	glucose	carbon	being	metabolized	through	glycolysis	to	pyruvate	
formation.	In	contrast,	≈	65%	of	glycolytic	carbon	resulted	in	pyruvate	formation	in	MCF10AT	
and	MCF10-CA1	cells(13).	The	transformed	cells	shunted	glucose	into	the	pentose	phosphate	
pathway	(PPP)	to	support	the	production	of	NADPH	for	redox	balance.	Isotopomer	labeling	of	
glutamate	revealed	that	TCA	cycle	flux	was	almost	2	fold	higher	in	transformed	cells	than	in	
MCF10A(13).	Additionally,	this	study	observed	that	the	transformed	cell	lines	have	a	2-	to	4-fold	
increase	in	carbon	flux	to	GSH	production,	despite	all	cells	in	the	study	having	similar	GSH	
concentrations.	This	indicates	that	the	HRAS-transformed	cells	experience	higher	glutathione	
turnover	relative	to	the	non-transformed	parental	cell	line(13).	Teegarden	and	colleagues	also	
found	that	RAS-transformed	MCF10AT	cells	undergo	higher	rates	of	glucose	uptake	but	shunt	
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glycolytic	carbon	into	3-phosphoglycerate	production(40).	It	is	unclear	if	these	results	conflict	
with	those	reported	by	Smith	and	colleagues,	because	different	measures	of	glycolysis	were	
taken.	Additionally,	the	expression	of	glucose-6-phosphate	dehydrogenase,	the	glycolytic	
enzyme	that	is	rate-limiting	for	glucose	flux	into	the	PPP,	was	45%	higher	in	HRAS-transformed	
MCF10AT	cells	relative	to	the	non-transformed	parental	cell	line.	This	is	consistent	with	the	
finding	of	Smith	and	colleagues	that	the	transformed	cells	divert	glucose	towards	the	PPP(40).	
These	studies	demonstrate	that	TCA	cycle	metabolism	in	HRAS-transformed	MCF	cells	is	less	
reliant	on	glycolytic	carbon	for	energy	generation.	Thus,	it	is	likely	that	non-transformed	
MCF10A	cells	drive	mitochondrial	metabolism	primarily	via	glucose	carbon,	whereas	their	
isogenic	transformed	counterparts	may	require	significant	contribution	from	glutamine	to	drive	
TCA	cycle	metabolism.	Furthermore,	the	observation	that	HRAS-transformed	MCF	cells	undergo	
higher	rates	of	glutathione	turnover	is	consistent	with	our	observation	that	disruption	of	
glutaminolysis	results	in	greater	glutathione	oxidation	in	these	cells.	Another	recent	publication	
traced	the	contribution	of	U-13C5-glutamine	to	γ-glutamylcysteine	in	MCF10A	cells	in	relation	to	
overexpressed	AKT	signaling	in	those	cells(41).	The	contribution	of	glutamine	to	γ-
glutamylcysteine	in	AKT-driven	cells	was	400%	higher	than	that	in	non-transformed	MCF10A	
cells,	suggesting	that	WT	MCF10A	undergo	slower	glutathione	turnover	and	produce	less	GSH	
from	glutamine-derived	glutamate(41).	Thus,	it	is	appears	likely	that	the	difference	in	
mitochondrial	matrix	glutathione	redox	responses	to	glutamine	deprivation	are	reflective	of	
DCIS	and	CA1D	cellular	need	for	glutamine	to	support	TCA	cycle	metabolism	and	glutathione	
biosynthesis.		
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Contributions	of	glutamine	to	cytosolic	redox	poise		
The	model	of	non-canonical,	transaminase-mediated	glutaminolysis	outlined	by	Son	and	
colleagues	describes	a	pathway	for	glutamine-derived	aspartate	to	preserve	cytosolic	redox	
homeostasis	in	KRAS-transformed	tumor	cells(9).	When	deprived	of	glutamine,	pancreatic	
adenocarcinoma	cells	underwent	a	greater	than	2-fold	increase	in	cytosolic	ROS	levels,	assessed	
via	DCFDA.	Glutamine-derived	aspartate	was	demonstrated	to	reduce	ROS	levels	by	stimulating	
NADPH	production	by	malic-enzyme	to	maintain	cytosolic	glutathione	antioxidant	savaging	
capacity(9).	Thus,	our	observation	of	a	reduction	in	cytosolic	glutathione	redox	upon	glutamine	
deprivation	in	MCF	DCIS	and	CA1D	cells	was	unexpected.	One	possible	explanation	is	that	
glutamine-deprived	cells	shift	their	metabolism	towards	greater	glycolytic	flux	to	compensate	
for	energy	deficits	during	glutamine	deprivation.	Enhanced	glycolysis	could	generate	glycolytic	
intermediates	available	to	enter	the	pentose	phosphate	pathway	and	produce	NADPH	to	
reduce	the	cytosolic	glutathione	system.	However,	no	significant	change	in	oxidation	of	the	
cytosolic	glutathione	pool	was	observed	in	MCF10A,	A549,	or	MiaPaCa-2	cells.	Although,	it	must	
be	acknowledged	that	the	capacity	of	Grx1-roGFP2	to	“sense”	redox	changes	below	5%	and	
above	95%	oxidation	is	not	fully	accurate(20).	Therefore,	because	cytosolic	Grx1-roGFP2	was	
greater	than	90%	reduced	in	MCF10A,	A549,	and	MiaPaCa-2	cells	at	baseline,	a	reductive	
response	to	glutamine	deprivation	may	have	been	missed.	It	is	assured,	however,	that	these	
cells	do	not	undergo	cytosolic	glutathione	oxidation	in	response	to	glutamine	deprivation.	
Furthermore,	the	data	presented	herein	support	the	conclusion	that	cytosolic	glutathione	redox	
homeostasis	is	exceedingly	robust	and	is	capable	of	resisting	various	treatments	that	oxidize	
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the	mitochondrial	glutathione	system.	Thus,	cytosolic	glutathione	may	be	efficiently	scavenging	
cytosolic	ROS	build	up	during	glutamine	deprivation.		
Antioxidant	mechanisms	of	alpha-ketoglutarate		
To	further	probe	the	glutaminolytic	pathway	preserving	mitochondrial	matrix	glutathione	redox	
homeostasis,	glutamine-deprived	A549	cells	were	supplemented	with	cell-available	dimethyl	α-
KG,	dimethyl	aspartate,	and	oxaloacetate	(which	is	naturally	cell-permeable).	Although	cytosolic	
glutathione	oxidation	was	not	observed	in	response	to	glutamine	deprivation,	the	“non-
canonical”	transaminase-driven	pathway	of	glutamine	utilization	could	theoretically	support	
matrix	redox	in	a	number	of	ways.	For	instance,	NADPH	produced	in	the	cytosol	could	shuttle	
reducing	power	into	the	matrix	in	the	form	of	malate	or	could	be	used	to	preserve	the	cytosolic	
pool	of	reduced	glutathione	that	is	available	for	export	to	the	mitochondria.	Another	potential	
route	of	glutaminolytic	antioxidant	defense	could	arise	via	an	anaplerotic	mechanism	in	which	
glutamine	supports	robust	TCA	cycle	metabolism	and	drives	the	mitochondrial	production	of	
reducing	equivalents.	A	third	potential	mechanism	includes	supplying	glutamate	to	support	GSH	
biosynthesis	and	provide	direct	antioxidant	defense.	
	When	glutamine-deprived	A549	cells	were	supplemented	with	α-KG,	Asp,	and	OAA,	only	
supplemental	α-KG	significantly	rescued	mitochondrial	matrix	glutathione	oxidation	and	
supported	GSH	content	during	24h	glutamine	deprivation.	Alpha-ketoglutarate’s	protective	
effect	on	glutathione	oxidation	during	glutamine	deprivation	likely	involves	both	TCA	cycle	
production	of	reducing	equivalents	via	alpha-ketoglutarate	dehydrogenase	and	stimulation	of	
glutathione	synthesis	via	glutamate	generation.	This	is	surmised	because	complete	inhibition	of	
glutathione	biosynthesis	via	BSO	did	not	produce	the	degree	of	glutathione	oxidation	seen	in	
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glutamine-deprived	A549	cells,	indicating	that	the	oxidation	observed	in	response	to	glutamine	
deprivation	is	not	attributable	to	glutathione	loss	alone.		
Alpha-ketoglutarate	can	yield	glutamate	via	backwards	reaction	through	glutamate	
dehydrogenase	and	transaminases.	The	km	for	the	backward	reaction	catalyzed	by	glutamate	
dehydrogenase	suggests	that	it	is	unlikely	to	occur	in	the	intracellular	environment,	but	this	
process	should	be	achievable	via	transamination.	Recently,	the	contribution	of	glutamine-
derived	glutamate	to	GSH	biosynthesis	in	A549	cells	was	quantified	via	[13C5]	isotope	labeling	of	
glutamate(24).	The	majority	of	glutathione	was	derived	from	glutamine:	after	36h	isotope	
incubation,	around	60%	of	intracellular	glutamate	and	80%	of	excreted	glutathione	was	[13C5]-
labeled.	Thus,	in	agreement	with	the	data	presented	herein,	A549	cells	are	extremely	reliant	on	
glutamine	to	maintain	glutathione	production.		
Inhibition	of	transamination	by	AOA,	which	inhibits	the	anaplerotic	entry	of	α-KG	to	the	TCA	
cycle	and	inhibits	a	route	of	glutamate	synthesis	from	α-KG,	blocks	the	ability	of	supplemental	
α-KG	to	abrogate	mitochondrial	matrix	oxidation	during	glutamine	deprivation.	This	supports	
the	conclusion	that	alpha-ketoglutarate	has	pleomorphic	roles	in	providing	antioxidant	
protection	to	the	mitochondrial	matrix.	A	recent	review	by	Dr.	Chi	V.	Dang	highlights	alpha-
ketoglutarate	metabolism	as	an	under-studied	avenue	of	tumor	cell	metabolism(42).	Because		
α-KG	shares	the	majority	of	its	molecular	structure	with	glutamine	and	is	readily	producible	
from	TCA	cycle	metabolism,	it	seems	likely	that	α-KG	metabolism	may	underwrite	many	
glutamine-driven	responses	in	tumor	cell	metabolism.		
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Contribution	of	glutaminolytic	pathways	to	mitochondrial	redox	homeostasis	
Pharmacologic	inhibitors	of	glutaminolysis	were	employed	to	assess	the	importance	of	
glutaminolytic	enzymes	in	the	maintenance	of	subcellular	redox	poise.	AOA	inhibits	cellular	
transaminase	activity,	BPTES	inhibits	glutaminase,	and	EGCG	inhibits	glutamate	dehydrogenase.	
Inhibition	of	these	pathways	produced	no	notable	cytosolic	glutathione	redox	responses,	which	
is	consistent	with	the	observed	non-response	to	24h	glutamine	deprivation.	Transaminase	
inhibition	via	AOA	resulted	in	strong	mitochondrial	matrix	glutathione	oxidation	on	par	with	
that	of	total	glutamine	deprivation.	This	indicates	that	transaminase-mediated	glutaminolysis	is	
necessary	for	the	maintenance	of	mitochondrial	matrix	redox	homeostasis.	Surprisingly,	
inhibition	of	glutaminase	activity,	which	should	limit	the	formation	of	glutamine-derived	
glutamate,	only	resulted	in	a	modest,	not	statistically	significant	oxidation	of	the	mitochondrial	
matrix.	EGCG	treatment	resulted	in	a	modest	reduction	in	mitochondrial	matrix	glutathione	
oxidation.	Although	KRAS-driven	tumor	cells	such	as	A549	are	described	to	preferentially	utilize	
mitochondria	GOT2	transaminase	for	the	production	of	α-KG	from	glutamate,	an	oxidative	
response	was	expected	in	response	to	inhibition	of	glutamate	dehydrogenase.	Gaglio	and	
colleagues	assessed	ROS	levels	following	treatment	with	EGCG	and	reported	a	differential	
response	based	on	KRAS	transformation	status(8).	When	treated	with	EGCG,	non-transformed	
NIH3T3	cells	displayed	decreased	ROS	levels,	but	KRAS-transformed	NIH3T3	cells	displayed	
increased	ROS	levels	as	assessed	by	DCFH2-DA.	One	possible	explanation	for	our	finding	is	that	
EGCG	is	a	relatively	non-specific	enzymatic	inhibitor	with	multiple	off-target	reactions,	including	
stimulation	of	GSH	biosynthesis,	which	could	reduce	the	mitochondrial	matrix	glutathione	
pool(43).		
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A549	cells	require	transaminase-mediated	production	of	α-KG	for	cell	division	
Glutamine	provides	growing	tumor	cells	with	nitrogen	for	nucleotide	synthesis,	carbon	for	
anaplerosis	and	energy	metabolism,	and	glutamate	for	GSH	biosynthesis(11,	12).	Proliferation	
of	A549	cells	was	observed	to	be	completely	reliant	on	glutamine	supplementation,	in	
agreement	with	previous	investigations(44,	45).	Supplementation	with	cell-available	
glutaminolytic	carbons	and	antioxidant	NAC	could	not	restore	proliferation	to	glutamine-
deprived	cells,	suggesting	that	neither	oxidative	stress	nor	cataplerotic	depletion	of	TCA	cycle	
components	are	responsible	for	the	halt	in	A549	cell	proliferation.	This	is	consistent	with	recent	
reports	outlining	an	S-phase	arrest	in	KRAS-transformed	tumor	cells(37-39).	The	cell	cycle	arrest	
checkpoint	is	activated	by	the	Ataxia	telangiectasia	and	Rad3	related	(ATR)	kinase	that	monitors	
nucleotide	pools	to	ensure	proper	DNA	synthesis(38).	Supplementation	with	
deoxyribonucleotides	during	glutamine	deprivation	overrides	this	checkpoint(38,	39).	A	recent	
publication	studying	the	KRAS-mutated	breast	cancer	cell	line	MDA-MB-231	suggests	that	the	
addition	of	membrane-permeable	dimethyl	aspartate,	a	glutaminolytic	precursor	for	purine	and	
pyrimidine	biosynthesis,	rescues	cell	proliferation	during	glutamine	deprivation(38).	However,	
this	was	not	observed	in	the	studies	of	A549	cell	proliferation	presented	above,	as	aspartate	
was	unable	to	rescue	cell	proliferation.	To	what	extent	this	represents	differences	in	A549	
versus	MDA-MB-231	cells,	RPMI	versus	DMEM	media,	or	the	use	of	L-aspartic	acid	dimethyl	
ester	hydrochloride	versus	L-aspartic	acid	β-methyl	ester	hydrochloride	is	unknown.	In	a	
separate	study,	Son	and	colleagues	monitored	proliferation	during	glutamine	deprivation	in	a	
panel	of	KRAS-transformed	cell	lines	that	showed	partial	rescue	of	cell	growth	when	provided	
with	α-KG	and	aspartate	or	oxaloacetate,	the	mitochondrial	precursor	to	transaminase-
130	
	
mediated	aspartate	production(9).	Additionally,	antioxidant	NAC	was	able	to	rescue	cell	
proliferation	during	glutamine	deprivation.	However,	in	our	study,	A549	cell	proliferation	could	
not	be	stimulated	by	similar	treatments,	indicating	cell-type	specific	variability	in	glutaminolytic	
requirements	for	proliferation.		
Pharmacologic	inhibition	of	glutaminase	activity	via	BPTES	slowed	A549	cell	growth,	in	
keeping	with	previous	observations(24).	Inhibition	of	glutamate	dehydrogenase	via	EGCG	
inhibited	cell	proliferation	and	was	cytotoxic	beyond	36h.	Similar	results	have	been	reported	in	
KRAS-transformed	NIH3T3	cells	in	which	supplemental	α-KG	supplementation	could	rescue	the	
toxicity(8).	However,	Son	and	colleagues	report	no	sensitivity	to	EGCG	in	a	panel	of	KRAS-
transformed	cell	lines(9).	Treatment	of	A549	cells	with	transaminase	inhibitor	AOA	in	complete	
medium	also	arrested	cell	growth,	but	did	not	induce	cytotoxicity.	This	has	been	reported	
previously	and	is	suggested	to	mimic	glutamine	deprivation	by	blocking	transaminase-mediated	
production	of	aspartate	and	the	entry	of	α-KG	into	the	TCA	cycle(8,	37).	In	agreement	with	this	
observation,	cells	in	full	medium	supplemented	with	α-KG	and	treated	with	AOA	were	able	to	
proliferate,	but	at	a	slower	rate.	Thus,	transamination-mediated	production	of	α-KG	is	required	
for	A549	lung	adenocarcinoma	cell	growth.			
Maintenance	of	cytosolic	redox	poise	throughout	chronic	glutathione	depletion		
Mitochondrial	matrix	and	cytosolic	glutathione	pools	of	A549	cells	respond	differently	to	
chronic	glutamine	deprivation	and	inhibition	of	glutathione	biosynthesis.	A549	cell	cytosolic	
glutathione	strongly	resists	oxidation	from	glutamine	deprivation	or	glutathione	depletion	over	
72h.	In	contrast,	the	mitochondrial	matrix	glutathione	pool	is	far	more	susceptible	to	oxidation.	
Cells	inhibited	in	glutathione	production	by	BSO	for	72h	underwent	drastic	mitochondrial	
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matrix	glutathione	oxidation,	indicating	mitochondrial	redox	poise	is	highly	dependent	on	
continued	GSH	production.	Surprisingly,	the	oxidative	response	of	mitochondrial	matrix	
glutathione	to	glutamine	deprivation	mostly	plateaued	after	24h.	This	level	of	oxidation	may	
activate	compensatory	mechanisms,	such	as	enhanced	glucose-metabolism,	to	provide	for	
mitochondrial	redox	homeostasis.		
It	is	counterintuitive	that	the	mitochondrial	matrix,	which	neither	contains	the	main	
subcellular	pool	of	glutathione,	nor	is	the	site	of	its	enzymatic	production,	should	oxidize	in	
response	to	glutamine	deprivation	while	the	cytosol	does	not(18).	However,	we	have	reported	
previously	that	cytosolic	oxidation	by	24h	treatment	with	BSO	is	dependent	on	p53	mutation	
status(26).	A549	cells	express	wild	type	p53	and,	thus,	should	be	expected	to	resist	cytosolic	
oxidation	via	glutathione	depletion(46).	However,	near	complete	GSH	depletion	occurs	within	
60h	in	A549	cells	deprived	of	glutamine	(47).	This	makes	the	absence	of	oxidation	observed	
with	72h	BSO	incubation	particularly	striking.			
	A	functional	basis	for	the	different	responses	of	mitochondrial	and	cytosolic	glutathione	
pools	to	glutathione	depletion	may	be	explained	by	the	ability	of	the	cytosolic	glutathione	pool	
to	excrete	oxidized	glutathione;	this	mechanism	is	not	available	to	mitochondria(18).	Thus,	
when	challenged	by	a	chronic	oxidative	threat,	cytosolic	glutathione	pools	in	p53wt	cells	may	be	
more	able	to	efficiently	re-reduce	or	excrete	oxidized	glutathione	to	maintain	redox	balance.	
Additionally,	RAS-transformed	tumor	cells	have	enhanced	antioxidant	capacities	and	can	divert	
glucose	metabolism	into	the	pentose	phosphate	pathway	to	produce	the	NADPH	necessary	to	
maintain	cytosolic	glutathione	homeostasis(8,	13,	48).	For	this	reason,	this	response	may	be	
cell-type	specific.	A	previous	investigation	employing	the	roGFP1	biosensor	in	primary	skin	
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fibroblasts	demonstrated	substantial	oxidation	of	both	the	mitochondrial	matrix	and	cytosolic	
glutathione	pools	following	72h	BSO	exposure(49).	Additionally,	complete	oxidation	of	cytosolic	
glutathione	was	also	observed	in	the	Arabidopsis	thaliana	plant	germinated	on	BSO-containing	
agar	plates	for	seven	days(50).		
Conclusion	
This	study	indicates	that	RAS-transformed	tumor	cells	have	an	enhanced	reliance	on	
glutaminolytic	transamination	for	the	maintenance	of	mitochondrial	redox	poise.	Mitochondria	
are	the	primary	subcellular	site	of	ROS	generation,	and	their	metabolic	function	is	closely	linked	
to	redox	homeostasis.	Thus,	disruption	of	glutamine	metabolism	may	yield	an	effective	strategy	
in	which	to	selectively	predispose	RAS-transformed	tumor	cells	to	oxidative	dysfunction.		
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4.6	Figures	
	
	
	
	
	
	
	
	
	
	
Figure	4.1:	Derivation	of	the	MCF10A/DCIS/CA1D	cell	series.		
MCF-10A	cells	are	non-transformed,	spontaneously	immortalized	breast	epithelial	cells	from	
which	the	T-24	HRAS	transformed	cell	line	MCF10AT	was	formed.	Serial	passage	and	
implantation	into	immunodeficient	mice	yielded	two	distinct	cell	lines	of	advanced	malignancy.	
MCFDCIS	cells	are	tumorigenic	and	non-metastatic.	MCFCA1D	cells	are	fully	metastatic	and	
invasive	when	inoculated	into	immunodeficient	mice.		
	
134	
	
	
	
Figure	4.2:	Glutamine	deprivation	results	in	mitochondrial	matrix	oxidation.	
A)	Glutamine	deprivation	(24h)	significantly	oxidizes	the	mitochondrial	matrix	of	MCF-DCIS	and	
CA1D	cells,	but	not	non-transformed	MCF-10A	cells.	Similar	oxidation	was	observed	in	KRAS-
transformed	A549	and	MiaPaCa-2	cells.	Alpha-ketoglutarate	supplementation	during	glutamine	
deprivation	attenuates	oxidation.	Representative	bars	are	the	mean	±	SEM	(n	≥	5,	P	=	.05).		B)	
24h	glutamine	deprivation	results	in	a	slight	reduction	in	cytosolic	glutathione	oxidation	in	
MCF-DCIS	and	CA1D	cells.	Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	.05).	
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Figure	4.3:	The	“non-canonical”	pathway	of	glutaminolysis	and	redox	homeostasis.	Glutamine	
is	converted	to	glutamate	via	glutaminase,	and	then	engages	GOT2/GOT1	transaminases	and	
the	associated	malate-aspartate	shuttle	to	ultimately	produce	cytosolic	malate.	Cytosolic	
Malate	can	boost	NADPH	production	via	malic	enzyme	for	redox	balance.	Adapted	from	(9).	
	
	
	
	
	
	
	
	
Figure	4.4:	Glutamine	deprivation	increases	mitochondrial	ROS	generation.		
Wild-type	A549	cells	were	deprived	of	glutamine	for	24h,	stained	with	MitoSOX	Red,	and	
assessed	via	flow	cytometry.	Glutamine-deprived	cells	had	a	>	33%	increase	in	superoxide	
production.	Representative	bars	are	the	mean	±	SEM	(n	=	2,	P	=	.05).	
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Figure	4.5:	24-hour	glutamine	deprivation	results	in	loss	of	glutathione	content.	Glutathione	
content	was	assayed	by	monobromobimane	thiol	staining	and	assessed	by	flow	cytometry.	
Cells	of	separate	tissues	have	different	amounts	of	glutathione	and	thus	raw	(not	background	
corrected)	MBB	fluorescence	data	were	normalized	to	control	(full	medium)	sample	
fluorescence	for	each	cell	type.	Glutamine	deprivation	(24h)	resulted	in	a	significant	loss	of	
glutathione	content	in	MCF	DCIS/CA1D,	A549,	and	MiaPaCa-2	cells,	but	not	in	MCF-10A	cells.	
Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	.05)	
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Figure	4.6:	Alpha-ketoglutarate	prevents	mitochondrial	matrix	oxidation	and	loss	of	
glutathione	content	during	glutamine	deprivation.		
A)	Mitochondrial	matrix	oxidation	and	B)	loss	of	glutathione	content	were	prevented	by	
supplemental	alpha-ketoglutarate.	Supplementation	with	downstream	glutaminolytic	carbons	
aspartate	and	oxaloacetate	did	not	yield	similar	responses.	Shifts	in	glutathione	content	were	
assayed	via	MBB	thiol	staining	and	corrected	for	background	and	off-target	fluorescence	via	
BSO	staining	intensity.	Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	.05).	
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Figure	4.7:	Pharmacologic	compounds	employed	to	inhibit	enzymatic	pathways	of	interest	
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Figure	4.8:	Mitochondrial	matrix	redox	poise	requires	glutaminolytic	transamination.		
A)	Cytosolic	and	B)	mitochondrial	matrix	glutathione	redox	responses	to	pharmacologic	
inhibitors	of	glutaminolysis.	Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	.05).	
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Figure	4.9:	Transamination	is	required	for	alpha-ketoglutarate-mediated	rescue	of	
mitochondrial	matrix	oxidation	from	glutamine	deprivation.	
Inhibition	of	transamination	via	AOA	results	in	mitochondrial	matrix	oxidation	and	blocks	alpha-
ketoglutarate-mediated	rescue	of	mitochondrial	matrix	oxidation	during	glutamine	deprivation.	
Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	.05).	
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Figure	4.10:	Glutaminolysis	supports	A549	cell	proliferation.	
A)	Glutamine	deprivation	halts	A549	cell	proliferation.	Proliferation	could	not	be	supported	
during	glutamine	deprivation	by	glutaminolytic	carbon	supplementation.	B)	Supplementation	
with	antioxidant	NAC	does	not	stimulate	proliferation	of	glutamine-deprived	A549	cells.	C)	
Pharmacologic	inhibitors	of	glutaminolysis	EGCG	and	AOA	inhibited	cell	proliferation,	and	
proliferation	was	slowed	by	BPTES.	Inhibition	of	GSH	biosynthesis	via	BSO	inhibited	A549	cell	
proliferation.	Representative	bars	are	the	mean	±	SEM	(n	=	8).	
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Figure	4.11:	Cytosolic	and	mitochondrial	glutathione	redox	responses	differ	greatly	to	chronic	
inhibition	of	GSH	biosynthesis.		Biosensor-expressing	A549	cells	were	exposed	to	72h	
glutamine	deprivation	or	72h	inhibition	of	glutathione	synthesis	via	incubation	with	BSO.	A)	
Cytosolic	redox	poise	is	unaltered	throughout	72h	glutamine	deprivation	and	inhibition	of	GSH	
biosynthesis.	Representative	bars	are	the	mean	±	SEM	(n	≥	4,	P	=	.05).	B)	Mitochondrial	
oxidation	progressively	worsens	throughout	inhibition	of	GSH	biosynthesis,	but	not	glutamine	
deprivation.	Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	.05).	
	
	
143	
	
4.7	References	
1.	 DeBerardinis	RJ,	Mancuso	A,	Daikhin	E,	Nissim	I,	Yudkoff	M,	Wehrli	S,	et	al.	Beyond	
aerobic	glycolysis:	Transformed	cells	can	engage	in	glutamine	metabolism	that	exceeds	
the	requirement	for	protein	and	nucleotide	synthesis.	Proceedings	of	the	National	
Academy	of	Sciences	of	the	United	States	of	America.	2007;104(49):19345-50.	
2.	 Wise	DR,	DeBerardinis	RJ,	Mancuso	A,	Sayed	N,	Zhang	X-Y,	Pfeiffer	HK,	et	al.	Myc	
regulates	a	transcriptional	program	that	stimulates	mitochondrial	glutaminolysis	and	
leads	to	glutamine	addiction.	Proceedings	of	the	National	Academy	of	Sciences	of	the	
United	States	of	America.	2008;105(48):18782-7.	
3.	 Yuneva	M,	Zamboni	N,	Oefner	P,	Sachidanandam	R,	Lazebnik	Y.	Deficiency	in	glutamine	
but	not	glucose	induces	MYC-dependent	apoptosis	in	human	cells.	Journal	of	Cell	
Biology.	2007;178(1):93-105.	
4.	 Gao	P,	Tchernyshyov	I,	Chang	T-C,	Lee	Y-S,	Kita	K,	Ochi	T,	et	al.	c-Myc	suppression	of	
miR-23a/b	enhances	mitochondrial	glutaminase	expression	and	glutamine	metabolism.	
Nature.	2009;458(7239):762-U100.	
5.	 Le	A,	Lane	AN,	Hamaker	M,	Bose	S,	Gouw	A,	Barbi	J,	et	al.	Glucose-independent	
glutamine	metabolism	via	TCA	cycling	for	proliferation	and	survival	in	B	cells.	Cell	
Metabolism.	2012;15(1):110-21.	
6.	 Yang	C,	Sudderth	J,	Dang	T,	Bachoo	RG,	McDonald	JG,	DeBerardinis	RJ.	Glioblastoma	
cells	require	glutamate	dehydrogenase	to	survive	impairments	of	glucose	metabolism	or	
Akt	signaling.	Cancer	Research.	2009;69(20):7986-93.	
7.	 Weinberg	F,	Hamanaka	R,	Wheaton	WW,	Weinberg	S,	Joseph	J,	Lopez	M,	et	al.	
Mitochondrial	metabolism	and	ROS	generation	are	essential	for	Kras-mediated	
tumorigenicity.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	
America.	2010;107(19):8788-93.	
8.	 Gaglio	D,	Metallo	CM,	Gameiro	PA,	Hiller	K,	Danna	LS,	Balestrieri	C,	et	al.	Oncogenic	K-
Ras	decouples	glucose	and	glutamine	metabolism	to	support	cancer	cell	growth.	
Molecular	Systems	Biology.	2011;7.	
9.	 Son	J,	Lyssiotis	CA,	Ying	H,	Wang	X,	Hua	S,	Ligorio	M,	et	al.	Glutamine	supports	
pancreatic	cancer	growth	through	a	KRAS-regulated	metabolic	pathway.	Nature.	
2013;496(7443):101-+.	
10.	 Hu	YM,	Lu	WQ,	Chen	G,	Wang	P,	Chen	Z,	Zhou	Y,	et	al.	K-ras(G12V)	transformation	leads	
to	mitochondrial	dysfunction	and	a	metabolic	switch	from	oxidative	phosphorylation	to	
glycolysis.	Cell	Research.	2012;22(2):399-412.	
11.	 DeBerardinis	RJ,	Cheng	T.	Q's	next:	the	diverse	functions	of	glutamine	in	metabolism,	
cell	biology	and	cancer.	Oncogene.	2010;29(3):313-24.	
12.	 Wise	DR,	Thompson	CB.	Glutamine	addiction:	a	new	therapeutic	target	in	cancer.	Trends	
in	Biochemical	Sciences.	2010;35(8):427-33.	
13.	 Richardson	AD,	Yang	C,	Osterman	A,	Smith	JW.	Central	carbon	metabolism	in	the	
progression	of	mammary	carcinoma.	Breast	Cancer	Research	and	Treatment.	
2008;110(2):297-307.	
14.	 Hensley	CT,	Wasti	AT,	DeBerardinis	RJ.	Glutamine	and	cancer:	cell	biology,	physiology,	
and	clinical	opportunities.	Journal	of	Clinical	Investigation.	2013;123(9):3678-84.	
144	
	
15.	 Trachootham	D,	Lu	W,	Ogasawara	MA,	Valle	NR-D,	Huang	P.	Redox	regulation	of	cell	
survival.	Antioxidants	&	Redox	Signaling.	2008;10(8):1343-74.	
16.	 Traverso	N,	Ricciarelli	R,	Nitti	M,	Marengo	B,	Furfaro	AL,	Pronzato	MA,	et	al.	Role	of	
glutathione	in	cancer	progression	and	chemoresistance.	Oxidative	medicine	and	cellular	
longevity.	2013;	Artcile	ID	972913,	2013.	
17.	 Lu	SC.	Glutathione	synthesis.	Biochimica	et	Biophysica	Acta	(BBA)	-	General	Subjects.	
2013;1830(5):3143-53.	
18.	 Mari	M,	Morales	A,	Colell	A,	Garcia-Ruiz	C,	Fernandez-Checa	JC.	Mitochondrial	
glutathione,	a	key	survival	antioxidant.	Antioxidants	&	Redox	Signaling.	
2009;11(11):2685-700.	
19.	 Estrela	JM,	Ortega	A,	Obrador	E.	Glutathione	in	cancer	biology	and	therapy.	Critical	
Reviews	in	Clinical	Laboratory	Sciences.	2006;43(2):143-81.	
20.	 Meyer	AJ,	Dick	TP.	Fluorescent	Protein-Based	Redox	Probes.	Antioxidants	&	Redox	
Signaling.	2010;13(5):621-50.	
21.	 Dooley	CT,	Dore	TM,	Hanson	GT,	Jackson	WC,	Remington	SJ,	Tsien	RY.	Imaging	dynamic	
redox	changes	in	mammalian	cells	with	green	fluorescent	protein	indicators.	Journal	of	
Biological	Chemistry.	2004;279(21):22284-93.	
22.	 Lukyanov	KA,	Belousov	VV.	Genetically	encoded	fluorescent	redox	sensors.	Biochimica	
Et	Biophysica	Acta-General	Subjects.	2014;1840(2):745-56.	
23.	 Lu	H,	Samanta	D,	Xiang	L,	Zhang	H,	Hu	H,	Chen	I,	et	al.	Chemotherapy	triggers	HIF-1-
dependent	glutathione	synthesis	and	copper	chelation	that	induces	the	breast	cancer	
stem	cell	phenotype.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	
States	of	America.	2015;112(33):E4600-E9.	
24.	 Sappington	DR,	Siegel	ER,	Hiatt	G,	Desai	A,	Penney	RB,	Jamshidi-Parsian	A,	et	al.	
Glutamine	drives	glutathione	synthesis	and	contributes	to	radiation	sensitivity	of	A549	
and	H460	lung	cancer	cell	lines.	Biochimica	Et	Biophysica	Acta-General	Subjects.	
2016;1860(4):836-43.	
25.	 Trachootham	D,	Zhou	Y,	Zhang	H,	Demizu	Y,	Chen	Z,	Pelicano	H,	et	al.	Selective	killing	of	
oncogenically	transformed	cells	through	a	ROS-mediated	mechanism	by	beta-
phenylethyl	isothiocyanate.	Cancer	Cell.	2006;10(3):241-52.	
26.	 Kolossov	VL,	Hanafin	WP,	Beaudoin	JN,	Bica	DE,	DiLiberto	SJ,	Kenis	PJA,	et	al.	Inhibition	
of	glutathione	synthesis	distinctly	alters	mitochondrial	and	cytosolic	redox	poise.	
Experimental	Biology	and	Medicine.	2014;239(4):394-403.	
27.	 Kolossov	VL,	Beaudoin	JN,	Hanafin	WP,	DiLiberto	SJ,	Kenis	PJA,	Gaskins	HR.	Transient	
light-induced	intracellular	oxidation	revealed	by	redox	biosensor.	Biochemical	and	
Biophysical	Research	Communications.	2013;439(4):517-21.	
28.	 Hedley	DW,	Chow	S.	Evaluation	of	methods	for	measuring	cellular	glutathione	content	
using	flow-cytometry.	Cytometry.	1994;15(4):349-58.	
29.	 Farkas	DL,	Wei	MD,	Febbroriello	P,	Carson	JH,	Loew	LM.	Simultaneous	imaging	of	cell	
and	mitochondrial-membrane	potentials.	Biophysical	Journal.	1989;56(6):1053-69.	
30.	 Anso	E,	Mullen	AR,	Felsher	DW,	Mates	JM,	Deberardinis	RJ,	Chandel	NS.	Metabolic	
changes	in	cancer	cells	upon	suppression	of	MYC.	Cancer	&	metabolism.	2013;1(1):7-.	
145	
	
31.	 Soule	HD,	Maloney	TM,	Wolman	SR,	Peterson	WD,	Brenz	R,	McGrath	CM,	et	al.	Isolation	
and	characterization	of	a	spontaneously	immortalized	human	breast	epithelial	cell	line,	
MCF-10.	Cancer	Research.	1990;50(18):6075-86.	
32.	 Dawson	PJ,	Wolman	SR,	Tait	L,	Heppner	GH,	Miller	FR.	MCF10AT:	A	model	for	the	
evolution	of	cancer	from	proliferative	breast	disease.	American	Journal	of	Pathology.	
1996;148(1):313-9.	
33.	 Miller	FR,	Soule	HD,	Tait	L,	Pauley	RJ,	Wolman	SR,	Dawson	PJ,	et	al.	Xenograft	model	of	
progressive	human	proliferative	breast	disease.	Journal	of	the	National	Cancer	Institute.	
1993;85(21):1725-32.	
34.	 Miller	FR,	Santner	SJ,	Tait	L,	Dawson	PJ.	MCF10DCIS.com	xenograft	model	of	human	
comedo	ductal	carcinoma	in	situ.	Journal	of	the	National	Cancer	Institute.	
2000;92(14):1185-6.	
35.	 Imbalzano	KM,	Tatarkova	I,	Imbalzano	AN,	Nickerson	JA.	Increasingly	transformed	MCF-
10A	cells	have	a	progressively	tumor-like	phenotype	in	three-dimensional	basement	
membrane	culture.	Cancer	Cell	International.	2009;9.	
36.	 Mukhopadhyay	P,	Rajesh	M,	Yoshihiro	K,	Hasko	G,	Pacher	P.	Simple	quantitative	
detection	of	mitochondrial	superoxide	production	in	live	cells.	Biochemical	and	
Biophysical	Research	Communications.	2007;358(1):203-8.	
37.	 Saqcena	M,	Mukhopadhyay	S,	Hosny	C,	Alhamed	A,	Chatterjee	A,	Foster	DA.	Blocking	
anaplerotic	entry	of	glutamine	into	the	TCA	cycle	sensitizes	K-Ras	mutant	cancer	cells	to	
cytotoxic	drugs.	Oncogene.	2015;34(20):2672-80.	
38.	 Patel	D,	Menon	D,	Bernfeld	E,	Mroz	V,	Kalan	S,	Loayza	D,	et	al.	Aspartate	rescues	S-
phase	arrest	caused	by	suppression	of	glutamine	utilization	in	KRas-driven	cancer	cells.	
Journal	of	Biological	Chemistry.	2016;291(17):9322-9.	
39.	 Gaglio	D,	Soldati	C,	Vanoni	M,	Alberghina	L,	Chiaradonna	F.	Glutamine	deprivation	
induces	abortive	S-phase	rescued	by	deoxyribonucleotides	in	K-Ras	transformed	
fibroblasts.	Plos	One.	2009;4(3).	
40.	 Zheng	W,	Tayyari	F,	Gowda	GAN,	Raftery	D,	McLamore	ES,	Porterfield	DM,	et	al.	Altered	
glucose	metabolism	in	Harvey-Ras	transformed	MCF10A	cells.	Molecular	Carcinogenesis.	
2015;54(2):111-20.	
41.	 Lien	EC,	Lyssiotis	CA,	Juvekar	A,	Hu	H,	Asara	JM,	Cantley	LC,	et	al.	Glutathione	
biosynthesis	is	a	metabolic	vulnerability	in	PI(3)K/Akt-driven	breast	cancer.	Nature	Cell	
Biology.	2016;18(5):572-+.	
42.	 Altman	BJ,	Stine	ZE,	Dang	CV.	From	Krebs	to	clinic:	glutamine	metabolism	to	cancer	
therapy	(vol	16,	pg	619,	2016).	Nature	Reviews	Cancer.	2016;16(12):773-.	
43.	 Fu	YM,	Zheng	SZ,	Lu	SC,	Chen	AP.	Epigallocatechin-3-gallate	inhibits	growth	of	activated	
hepatic	stellate	cells	by	enhancing	the	capacity	of	glutathione	synthesis.	Molecular	
Pharmacology.	2008;73(5):1465-73.	
44.	 Ahmad	S,	White	CW,	Chang	LY,	Schneider	BK,	Allen	CB.	Glutamine	protects	
mitochondrial	structure	and	function	in	oxygen	toxicity.	American	Journal	of	Physiology-
Lung	Cellular	and	Molecular	Physiology.	2001;280(4):L779-L91.	
45.	 Ogunlesi	F,	Cho	C,	McGrath-Morrow	SA.	The	effect	of	glutamine	on	A549	cells	exposed	
to	moderate	hyperoxia.	Biochimica	Et	Biophysica	Acta-Molecular	Basis	of	Disease.	
2004;1688(2):112-20.	
146	
	
46.	 Breen	L,	Heenan	M,	Amberger-Murphy	V,	Clynes	M.	Investigation	of	the	role	of	p53	in	
chemotherapy	resistance	of	lung	cancer	cell	lines.	Anticancer	Research.	
2007;27(3A):1361-4.	
47.	 Kang	YJ,	Emery	D,	Enger	MD.	Buthionine	sulfoximine	induced	growth-inhibition	in	
human	lung-carcinoma	cells	does	not	correlate	with	glutathione	depletion.	Cell	Biology	
and	Toxicology.	1991;7(3):249-61.	
48.	 Recktenwald	CV,	Kellner	R,	Lichtenfels	R,	Seliger	B.	Altered	detoxification	status	and	
increased	resistance	to	oxidative	stress	by	K-Ras	transformation.	Cancer	Research.	
2008;68(24):10086-93.	
49.	 Verkaart	S,	Koopman	WJH,	Cheek	J,	van	Emst-de	Vries	SE,	van	den	Heuvel	LWPJ,	
Smeitink	JAM,	et	al.	Mitochondrial	and	cytosolic	thiol	redox	state	are	not	detectably	
altered	in	isolated	human	NADH:ubiquinone	oxidoreductase	deficiency.	Biochimica	et	
Biophysica	Acta	(BBA)	-	Molecular	Basis	of	Disease.	2007;1772(9):1041-51.	
50.	 Meyer	AJ,	Brach	T,	Marty	L,	Kreye	S,	Rouhier	N,	Jacquot	JP,	et	al.	Redox-sensitive	GFP	in	
Arabidopsis	thaliana	is	a	quantitative	biosensor	for	the	redox	potential	of	the	cellular	
glutathione	redox	buffer.	Plant	Journal.	2007;52(5):973-86.	
	
	 	
147	
	
Appendix	A:	Oncogenic	EGFR	signaling	and	metabolic	contributions	to	redox	homeostasis	
A.1	Introduction	
The	epidermal	growth	factor	receptor	(EGFR,	also	known	as	HER-1)	is	a	cell	surface	tyrosine	
kinase	receptor	that	is	frequently	mutated	in	many	epithelial	cancers(1-3).	EGFR-driven	
signaling	networks	are	a	particularly	well-understood	node	of	cellular	signaling,	and	the	
epidermal	growth	factor	receptor	itself	is	viewed	as	the	prototypical	tyrosine	kinase	receptor.	
Receptor	signaling	is	initiated	by	ligand	binding,	which	results	in	receptor	dimerization	and	
autophosphorylation	of	cytoplasmic	tyrosine	residues(3).	Phosphorylated	tyrosines	may	serve	
as	docking	sites	for	various	signaling	molecules	that	initiate	downstream	signaling	cascades(3).		
Oncogenic	EGFR	signaling	occurs	following	gene	mutation,	gene	amplification,	and	protein	
overexpression(3).	Mutated	EGFR	is	especially	prevalent	in	glioblastoma,	the	most	aggressive	
and	deadly	form	of	brain	cancer,	for	which	treatment	regimens	have	done	little	to	advance	the	
current	median	survival	time	of	14	months(4,	5).	Epidermal	growth	factor	receptor	
overexpression	or	vIII	mutation	are	reported	in	the	majority	of	glioblastoma	cases(2).	The	EGFR	
vIII	mutation	results	from	an	in-frame	deletion	of	exons	2-7	and	codes	for	a	truncated	receptor	
with	no	ligand-binding	domain.	Oncogenic	EGFR	results	in	ligand-independent	receptor	firing	
and	low-level	constitutive	activation(2).		
The	epidermal	growth	factor	receptor	lies	upstream	of	a	large	number	of	signaling	cascades,	
including	the	RAS-Raf-MAPK	and	PI3K-AKT	pathways,	and	thus	constitutive	EGFR	signaling	
results	in	aggressive	proliferation	and	tissue	invasion(2,	6).	Because	these	mutations	are	so	
prevalent	and	tumor-specific	(vIII	mutations	are	never	found	in	healthy	tissues),	they	have	been	
the	target	of	many	rationally-designed	chemotherapeutics(2).	For	example,	Erlotinib	is	a	
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selective	inhibitor	of	the	EGFR	ErbB1	tyrosine	kinase	that	is	approved	for	the	treatment	of	
locally	advanced	or	metastatic	non-small	cell	lung	cancer(1).	When	compared	to	other	
prominent	oncogenic	mutations,	the	metabolic	implications	of	oncogenic	EGFR	signaling	are	
less	understood.	The	data	presented	herein	suggest	that	mutated	EGFR	signaling	induced	either	
by	vIII	mutation	or	receptor	overexpression	results	in	less	metabolic	flexibility	and	an	enhanced	
need	for	both	glutamine	and	glucose	to	maintain	cellular	glutathione	redox	homeostasis.		
A.2	Methods		
Cell	culture	
Glioblastoma	cells	U87-MG,	U87EGFR,	and	U87vIII	were	provided	by	Dr.	Nathan	Price	(Institute	
for	Systems	Biology,	Seattle,	WA)	by	way	of	Dr.	Brendan	Harley	(University	of	Illinois,	Urbana,	
IL).	Cells	were	cultured	at	37°C	with	5%	CO2	and	passaged	routinely	at	70-80%	confluence.	Cells	
were	regularly	cultured	in	DMEM	containing	1.5	g/L	bicarbonate,	4.5	g/L	glucose,	1	mM	
pyruvate,	NEAA	mixture,	and	10	mM	HEPES	buffer.	Glutamine	deprivation	experiments	were	
performed	in	similar	glutamine-free	media	supplemented	with	10%	dialyzed	FBS.	Glucose-free	
experiments	were	performed	in	similar	glucose-free	medium	supplemented	with	10mM	
galactose.		
Genetic	constructs	and	transfection	
The	same	genetic	constructions	and	transfection	protocols	as	presented	in	section	2.2	were	
used.		
Flow	cytometry	data	collection	and	statistical	analysis	
The	same	imaging	and	data	analysis	protocols	as	presented	in	section	4.2	were	used.	
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A.3	Results		
These	studies,	which	are	similar	to	those	performed	in	chapter	4,	were	designed	to	investigate	
how	oncogenic	EGFR	signaling	alters	metabolic	requirements	for	redox	balance.	An	isogenic	cell	
series	built	upon	the	U87-MG	glioblastoma	genetic	background	and	transfected	with	cytosolic	
and	mitochondrial	matrix-targeted	Grx1-roGFP2	was	used.	The	U87-MG	cells	(referred	to	
herein	as	WT-U87)	do	not	express	EGFR,	whereas	two	isogenic	derivative	cell	lines	express	
mutant	EGFR(7).	The	U87-EGFR	cells	ectopically	over-express	wild	type	EGFR,	and	U87vIII	cells	
stably	express	the	vIII	mutation.	Figure	A.1	displays	a	western	blot	confirming	EGFR	expression	
performed	by	the	investigator	who	supplied	these	cells(7).	The	absence	of	EGFR	expression	in	
WT-U87	and	the	smaller	molecular	weight	of	the	truncated	vIII	protein	are	particularly	
notable(7).		
A.3.1	Mutated	EGFR	increases	U87	cell	reliance	on	glutamine	to	maintain	mitochondrial	
matrix	redox	homeostasis		
The	three	isogenic	U87	cell	lines	were	exposed	to	24h	glutamine	deprivation	(Figure	A.2).	The	
WT-U87	and	U87vIII	cells	share	a	similar	baseline	glutathione	redox	potential,	whereas	
U87EGFR	cells	are	significantly	more	oxidized	at	rest.	Differential	redox	responses	of	
mitochondrial	matrix	glutathione	to	24h	glutamine	deprivation	were	observed	in	the	U87	cell	
series.	Mitochondrial	redox	responses	segregated	according	to	EGFR-signaling	status.	The	WT-
U87	cell	line	underwent	a	small	and	not	statistically	significant	oxidation	of	6%.	The	EGFR-
driven	cell	lines,	U87vIII	and	U87EGFR,	robustly	responded	to	24h	glutamine	deprivation,	
undergoing	17.5%	and	14%	mitochondrial	matrix	oxidation,	respectively.	In	contrast,	cytosolic	
redox	poise	was	not	affected	by	glutamine	deprivation	in	the	three	U87	cell	lines.	
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A.3.2	Mutant	EGFR	signaling	results	in	glycolytic	addiction		
Hyper	proliferative	tumor	cells	have	an	enhanced	reliance	on	glycolysis	for	energy	
production(8).	Although	the	“Warburg	effect”	is	nearly	ubiquitous	in	transformed	cells,	many	
tumor	cells	maintain	metabolic	flexibility	to	reversibly	switch	between	fermentative	and	
oxidative	energy	generation(8).	Depriving	cell	cultures	of	glucose	while	providing	galactose	and	
glutamine	as	respiratory	substrates	tests	this	metabolic	flexibility.	Doing	so	significantly	blocks	
glycolytic	contributions	to	ATP	production,	because	galactose	must	enter	glycolysis	through	the	
much	slower	Leloir	pathway,	forcing	cells	to	shift	their	metabolism	towards	oxidative	
phosphorylation	for	efficient	ATP	generation(9).		
To	investigate	metabolic	substrate	preference	and	the	ability	to	rely	upon	oxidative	
phosphorylation	for	ATP	generation,	the	U87	cell	series	was	cultured	in	glucose-free	medium	
supplemented	with	galactose	and	glutamine.	When	exposed	to	galactose/glutamine	medium,	
WT-U87	mitochondrial	matrix	redox	homeostasis	and	cell	viability	remained	unchanged	(Figure	
A.3).	In	contrast,	U87vIII	and	U87EGFR	cells	underwent	a	drastic	response.	When	U87vIII	and	
U87EGFR	cells	were	gated	via	FSC-A	versus	SC-A	plots	for	visualization	during	flow	cytometry,	
two	distinct	cell	populations	emerged.	The	first	population	was	positioned	according	to	normal,	
healthy	cells	and	represented	≈	35%	of	the	population.	These	cells	had	baseline	redox	
potentials	highly	similar	to	the	full	medium	control	cells	(marked	“healthy”).	However,	a	larger	
population	representing	≈	65%	of	the	sample	scattered	outside	the	normal	range,	indicating	
poor	cell	size	and	shape.	This	larger	population	was	drastically	oxidized,	and	propidium	iodide	
staining	indicated	the	majority	(63%)	of	that	sub	population	was	dead	(data	not	shown).	
Additionally,	pyruvate	supplementation	to	the	glucose-free	medium	did	not	significantly	affect	
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these	outcomes	(data	not	shown).	This	study	demonstrates	the	reliance	of	EGFR-driven	
glioblastoma	cells	on	glycolysis;	when	deprived	of	glucose	but	supplied	with	adequate	
respiratory	substrates,	EGFR-driven	U87	cells	underwent	extreme	oxidation	of	mitochondrial	
matrix	glutathione	and	cell	death.	In	contrast,	WT-U87	cells	appear	to	be	more	metabolically	
flexible,	likely	have	a	larger	mitochondrial	reserve	capacity,	and	are	less	reliant	on	glycolytic	
ATP	generation	for	the	preservation	of	redox	poise.	Thus,	metabolic	therapies	directed	against	
EGFR-driven	glycolytic	metabolism	may	push	glioblastoma	cells	into	metabolic	crisis	while	
sparring	normal	cells.		
A.4	Discussion		
These	studies	demonstrate	EGFR-driven	differences	in	metabolic	requirements	to	maintain	
redox	homeostasis.	Both	overexpression	and	vIII	activation	of	EGFR	resulted	in	increased	
cellular	reliance	on	glutamine	to	maintain	mitochondrial	matrix	redox	poise,	and	an	absolute	
requirement	for	glycolytic	energy	production	to	maintain	cell	viability.	Sustained	EGFR	signaling	
may	function	via	a	number	of	signaling	pathways,	including	enhanced	RAS	activation,	to	
increase	U87vIII/U87EGFR	cellular	reliance	on	glutamine	to	maintain	mitochondrial	matrix	
glutathione	redox	poise.		
The	drastic	response	of	EGFR-driven	cells	exposed	to	glycolytic	deprivation	is	notable.	Large	
mitochondrial	oxidation	and	cell	death	occurs	within	24	hours	of	glucose	deprivation	in	U87vIII	
and	EGFR	cells,	despite	ample	availability	of	respiratory	substrates,	while	WT-U87	redox	poise	
was	unaffected.	Furthermore,	the	observation	that	pyruvate	did	not	significantly	alter	this	
response	suggests	that	cytosolic	and	mitochondrial	NADH	production	via	lactate	
dehydrogenase	and	pyruvate	dehydrogenase,	respectively,	could	not	rescue	these	cells	from	
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energetic	crisis.	Although	both	of	these	sources	of	NADH	should	be	readily	available	to	drive	
ATP	production	via	oxidative	phosphorylation	in	the	electron	transport	chain,	U87vIII	and	EGFR	
cells	appear	particularly	reliant	on	glycolytic	substrate	level	phosphorylation	for	energy	
generation.	This	may	be	due	to	sustained	EGFR	downstream	signaling	through	AKT,	a	well-
known	regulator	of	glycolysis	that	modulates	glucose	import	via	Glut1	and	the	overall	glycolytic	
tone	of	cancer	cells	via	phospho-fructokinase-1	(PFK-1)(10).	 	
These	data	demonstrate	unique	metabolic	responses	to	EGFR	signaling	in	an	isogenic	
glioblastoma	cell	background.	Further	research	into	the	metabolic	consequences	of	EGFR	
singling	in	glioblastoma	may	uncover	further	therapeutic	strategies	to	slow	tumor	spread	and	
sensitize	tumors	to	cell	killing.	The	preliminary	data	herein	serve	as	a	foundation	for	further	
investigations	into	the	metabolic	pathways	promoting	tumor	cell	survival,	invasion,	and	
migration	being	conducted	by	the	Gaskins/Kenis	laboratory	in	collaboration	Dr.	Brendan	
Harley’s	research	group.	
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A.5	Figures	
	
	
Figure	A.1:	Immunoblot	of	EGFR	expression	in	the	isogenic	U87	cell	series.	U87MG	
glioblastoma	cells	(referred	herein	as	WT-U87)	do	not	display	EGFR	expression.	Isogenic	
derivative	cells	lines	U87EGFR	and	U87vIII	robustly	express	mutant	EGFR.	The	EGFR	vIII	
mutation	codes	for	a	truncated,	constructively	active	EGFR	receptor,	and	thus	this	protein	has	a	
lower	molecular	weight	and	runs	further	down	the	lane.	Adapted	from	(7).	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	A.2:	Epidermal	growth	factor	signaling	increases	reliance	on	glutamine	or	maintenance	
of	mitochondrial	matrix	glutathione	redox	poise.	Cells	of	the	isogenic	U87	cell	line	series	differ	
in	mitochondrial	redox	responses	to	24h	glutamine	deprivation.	U87vIII	and	U87EGFR	cells	with	
activated	EGFR	undergo	a	robust	and	significant	oxidation	in	response	to	glutamine	deprivation;	
WT-U87	cells	do	not.	Glutamine	deprivation	did	not	cause	significant	cytosolic	glutathione	
redox	responses	in	the	U87	cell	lines.	Representative	bars	are	the	mean	±	SEM	(n	≥	3,	P	=	0.05).		
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Figure	A.3:	Epidermal	growth	factor	signaling	drives	reliance	on	glycolytic	energy	production	
for	cell	homeostasis.	Cells	of	the	isogenic	U87	cell	line	series	were	cultured	in	glucose-free	
medium	with	added	galactose.	The	WT-U87	cells	maintained	mitochondrial	redox	poise	while	
EGFR-driven	U87vIII	and	U87EGFR	cells	underwent	energetic	crisis,	resulting	in	two	distinct	flow	
cytometry	scatter	plot	populations:	“healthy”	cells	of	normal	size	and	shape,	and	“unhealthy	
cells”	that	are	extremely	oxidized.	Representative	bars	are	the	normalized	mean	±	SEM	(n	=	2,	P	
=	0.05).	
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Appendix	B:	Glutathione	redox	responses	to	chemotherapeutic	quinone	administration	
B.1	Introduction		
Generating	pathologic	reactive	oxygen	species	in	tumor	cells	is	a	proven	anticancer	strategy(1).	
Tumors	cells	inherently	undergo	increased	oxidative	stress	compared	to	non-neoplastic	cells	
because	of	their	genetic	instability,	metabolic	dysfunction,	and	hyperproliferative	phenotype.	
Enhanced	ROS	levels	in	transformed	cells	are	associated	with	tumor	aggressiveness	and	poorer	
patient	prognosis;	however,	because	antioxidant	mechanisms	are	already	stressed	in	tumor	
cells,	pathologic	ROS	generation	can	be	leveraged	therapeutically	to	kill	tumor	cells(1,	2).	Thus,	
the	efficacy	of	ROS-generating	chemotherapeutics	rests	on	the	notion	that	upsetting	redox	
balance	in	tumor	cells	should	be	achievable	by	spiking	ROS	levels	sufficiently	enough	to	damage	
tumor	cells,	but	without	exceeding	the	antioxidant	capacity	of	healthy	cells(3-6).		
Many	compounds,	such	as	doxorubicin,	elesclomol,	and	fenretinide,	generate	ROS	to	kill	
tumor	cells.	However,	to	increase	the	therapeutic	window	for	chemotherapeutic	
administration,	ROS-generating	compounds	need	enhanced	specificity	for	targeting	
transformed	cells.	Towards	this	end,	chemotherapeutic	bioreductable	quinones	target	the	
cytosolic	flavoenzyme	NAD(P)H:quinone	oxidoreductase-1	(NQO1)	to	selectively	increase	ROS	
generation	in	malignant	cells.	In	normal	cells,	NQO1	is	an	Nrf2	target	gene	that	is	inducibly	
expressed	in	response	to	oxidative	stress.	NQO1	serves	to	detoxify	quinones	by	catalyzing	their	
two-electron	reduction	to	hydroquinone,	which	can	be	glutathionylated	and	excreted	from	the	
cell(7,	8).	Chemotherapeutic	quinones	are	redirected	by	NQO1	into	a	"futile	redox	cycle"	in	
which	hydroquinone	spontaneously	re-oxidizes	to	parental	compounds,	producing	
superoxide(9).	Figure	B.1	displays	one	such	chemotherapeutic	quinone,	deoxynyboquinone	
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(DNQ),	reacting	with	NQO1	and	generating	unstable	hydroquinone,	which	redox	cycles	in	the	
cytosol	to	form	superoxide(9).		
Increased	basal	expression	of	NQO1	in	many	cancers	provides	chemotherapeutic	quinones	
with	enhanced	tumor	specificity(9).	Although	chemotherapeutic	quinones	display	greater	
cancer	specificity	than	more	conventional	chemotherapeutic	agents,	because	NQO1	is	inducibly	
expressed	by	all	cells,	quinones	are	not	immune	from	the	off-target	effects	that	limit	
conventional	chemotherapeutic	treatment	windows.	Additionally,	NQO1	may	compete	with	
other	cellular	reductases	to	react	with	these	quinones,	and	the	absolute	contribution	of	NQO1	
to	quinone-induced	cell	death	is	unclear(9).	Thus,	bioreductable	quinones	with	enhanced	
specificity	for	NQO1	are	needed.		
A	collection	of	rationally	designed	chemotherapeutic	derivatives	of	DNQ	were	synthesized,	
analyzed	for	predicted	NQO1	reactivity,	and	tested	in	cell	culture	for	NQO1-directed	
cytotoxicity(9).	Quinones	with	optimal	“hybrid	donor-acceptor	distance”	
react	most	efficiently	with	the	NQO1	enzyme(9,	10).	Twenty-six	DNQ	derivatives	were	assayed	
and	ranged	greatly	in	efficacy.	A	correlation	was	found	between	NQO1	reactivity	and	tumor	cell	
cytotoxicity.	A	compound	highly	similar	to	DNQ	but	with	an	isobutyl	group	attached,	called	
isobutyl-DNQ	(IB-DNQ,	or	DNQ	2),	had	similar	reaction	efficiency	and	cytotoxicity	to	DNQ.	In	
contrast,	analogues	with	bulky	chemical	groups	attached,	such	as	DNQ	13,	were	predicted	to	
react	less	efficiently	and	were	less	cytotoxic	to	tumor	cells	in	culture(9).	However,	the	original	
DNQ	quinone	chemotherapeutic	compound	emerged	as	the	most	efficacious	and	was	10	times	
more	effective	in	inducing	NQO1-dependent	cancer	cell	cytotoxicity	than	the	more	recognized	
quinone	chemotherapeutic,	1,2-naphthoquinone	(β-lapachone)(9).	
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Chemotherapeutic	compounds	can	be	derived	to	react	efficiently	with	the	NQO1	enzyme,	
but	the	contributions	of	off-target	oxidative	responses	from	quinone-based	chemotherapeutics	
are	not	fully	characterized.	For	instance,	the	role	of	mitochondria	in	respiratory	complex	redox	
drug	activation,	ROS	production,	and	loss	of	mitochondrial	membrane	potential	has	been	
suggested	in	β-lapachone-induced	cell	death(11,	12).	Because	of	its	ability	to	reliably	monitor	
subcellular	oxidative	responses,	the	Grx1-roGFP2	biosensor	is	an	ideal	tool	for	extending	
studies	into	the	cellular	effects	of	quinone	administration.	We	recently	published	a	paper	
investigating	glutathione	redox	responses	to	β-lapachone	and	DNQ	administration(13).	We	
found	that	A549	lung	adenocarcinoma	cells	and	MiaPaCa-2	pancreatic	carcinoma	cells	undergo	
unique	subcellular	glutathione	redox	responses	to	chemotherapeutic	quinone	administration;	
cytosolic	and	mitochondrial	matrix	oxidation	by	DNQ	is	fully	NQO1-dependant	in	MiaPaCa-2	
cells,	whereas	A549	cells	undergo	NQO1-independent	mitochondrial	matrix	oxidation(13).	
Oxidation	of	A549	cell	mitochondrial	matrix	corresponds	with	mitochondrial	matrix	ROS	release	
and	is	accompanied	by	an	increase	in	mitochondrial	membrane	potential.	We	also	reported	
that	both	DNQ	and	β-lapachone	oxidize	the	thiol-based	Grx1-roGFP2	probe	in	an	NQO1-
indepedent	manner	when	used	at	full	micromolar	concentrations,	such	as	β	-lapachone’s	IC50	
concentration	of	2	μM.	This	was	demonstrated	by	studying	the	redox	reaction	to	varying	
concentrations	of	DNQ	and	β-lapachone	in	the	presence	of	NQO1	inhibitors	dicumerol	and	
compound	ES936	and	in	NQO1-null	CHO	cells.	Thus,	at	higher	concentrations,	
chemotherapeutic	quinones	may	react	undesirably	with	intracellular	thiols	in	an	off-target	
manner.	However,	DNQ’s	specificity	and	reactivity	for	NQO1	allows	use	of	drug	concentrations	
far	below	this	threshold,	thereby	reducing	the	risk	for	off-target	effects(13).		
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The	data	below	introduce	a	study	of	the	mitochondrial	response	to	DNQ	administration	and	
demonstrate	the	use	of	the	Grx1-roGFP2	biosensor	as	a	screening	tool	for	ROS-producing	
chemotherapeutics.	
B.2	Methods	
Cell	culture,	genetic	constructs	and	transfection,	and	data	collection	and	analysis	
Protocols	presented	in	section	2.2	were	used.			
Chemicals	and	reagents	
Unless	stated	otherwise,	reagents	were	obtained	from	Sigma-Aldrich	(St.	Louis,	MO).	DNQ	and	
its	derivatives	were	kind	gifts	of	Dr.	Paul	Hergenrother	(University	of	Illinois,	Urbana,	IL).	All	
quinones	were	dissolved	in	dimethyl	sulfoxide.	The	cationic	dye	tetramethylrhodamine	ethyl	
ester	(TMRE)	for	assessing	mitochondrial	membrane	potential	was	purchased	from	Life	
Technologies	(Grand	Island,	NY)	and	was	prepared	according	to	the	manufacturer’s	suggestions.	
Carbonyl	cyanide	3-chlorophenylhydrazone	(CCCP)	was	resuspended	according	to	the	
manufacturer’s	(Sigma-Aldrich)	suggestion.	
Measurement	of	mitochondrial	membrane	potential	
The	cationic,	membrane-permeable,	fluorescent	dye	TMRE	accumulates	in	mitochondria	due	to	
their	negative	charge	and,	thus,	can	be	used	to	assay	changes	in	mitochondrial	membrane	
potential(14).	A549	cells	in	Dulbecco's	phosphate-buffered	saline	supplemented	with	5%	FBS	
and	10	mM	glucose	were	exposed	to	50	nM	TMRE	and	incubated	with	0.6	μM	DNQ.	To	
demonstrate	the	efficacy	of	using	TMRE	to	study	changes	in	mitochondrial	membrane	
potential,	the	ionophore	CCCP	(25	μM)	was	used	as	a	negative	control	to	dissipate	
mitochondrial	membrane	potential.	Fluorescence	was	assessed	via	a	BD	LSR	II	(Becton	Dickson,	
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San	Jose,	CA)	flow	cytometer.	A	solid-state	blue	488	nm	laser	was	used	to	excite	the	TMRE	dye.	
Fluorescence	was	collected	using	575/26	nm	bandpass	filter	along	with	a	550	nm	long-pass	
dichroic	splitter.	Data	were	analyzed	using	FACS	Express	Version	3	(De	Novo	Software,	
Glendale,	CA).	
Microscopy	data	collection	and	statistical	analysis	
The	imaging	and	data	analysis	protocols	as	presented	in	section	4.2	were	used.	
B.3	Results	
B.3.1	DNQ	hyperpolarizes	the	mitochondrial	membrane	potential	
Administration	of	DNQ	to	NQO1-overexpressing	A549	cells	elicited	a	robust	cytosolic	oxidation,	
in	keeping	with	the	drug’s	mechanism	of	“redox	cycling”	with	cytosolic	NQO1	to	produce	
superoxide.	Cytosolic	superoxide	is	dismutated	via	cytosolic	superoxide	dismutase	to	hydrogen	
peroxide,	which	will	be	scavenged	by	the	glutathione	system	and	sensed	by	the	Grx1-roGFP2	
biosensor(15,	16).	However,	smaller	yet	still	significant	alterations	to	the	mitochondrial	matrix	
targeted	redox	biosensor	were	observed	alongside	cytosolic	oxidation	following	DNQ	
administration.	Although	it	is	possible	that	robust	cytosolic	superoxide	generation	could	
produce	H2O2	to	diffuse	into	the	mitochondrial	matrix,	this	mechanism	seems	unlikely	given	the	
antioxidant	defense	of	the	cytosol	and	mitochondrial	intermembrane	space.	In	addition,	the	
mitochondrial	redox	response	to	DNQ	administration	was	observed	even	when	the	cytosolic	
ROS	generation	was	abrogated	via	pharmacologic	inhibition	of	NQO1	with	dicumarol	and	
compound	ES936	(data	not	shown).	This	finding	suggests	that	DNQ	is	eliciting	NQO1-
independent,	off-target	oxidation	of	the	mitochondrial	compartment.		
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To	further	investigate	NQO1-independent	mitochondrial	oxidation	by	DNQ,	mitochondrial	
membrane	potential	was	monitored	in	response	to	DNQ	administration	(Figure	B.2).	The	
cationic,	membrane-permeable,	fluorescent	dye	TMRE	accumulates	in	mitochondria	due	to	
their	negative	charge	in	an	electrochemical	process	governed	by	the	Nernst	equation(14).	Thus,	
TMRE	dye	cannot	accumulate	in	depolarized	mitochondria	due	to	their	loss	of	charge.	
Mitochondrial	membrane	potential	was	dissipated	in	A549	cells	via	addition	of	25	μM	of	the	
protonophore	CCCP,	providing	a	negative	control	(Figure	B.2A)(17).	A549	cells	were	stained	
with	TMRE	dye,	administered	0.6	uM	DNQ,	and	then	assessed	at	various	time	points	for	TMRE	
fluorescence	(Figure	B.2B).	Treatment	with	DNQ	resulted	in	a	large	increase	in	mitochondrial	
membrane	potential	that	remained	elevated	compared	to	untreated	control	cell	values	for	
greater	than	one	hour.		
B.3.2	Glrx1-GFP2	is	an	efficient	screening	tool	for	ROS-producing	chemotherapeutics		
Pharmacologic	inhibition	of	NQO1	via	dicumarol	and	compound	ES936	fully	abrogates	DNQ-
induced	oxidation	of	the	A549	cell	cytosolic	compartment	when	applied	at	0.6	μM,	10x	DNQ’s	
IC50	concentration(13)	(data	not	shown).	This	indicates	DNQ’s	tremendous	specificity	for	NQO1	
for	producing	oxidative	responses	in	the	cytosol.	To	further	demonstrate	the	relationship	
between	NQO1	specificity	and	cytosolic	ROS	generation	by	DNQ,	biosensor-expressing	A549	
cells	were	exposed	to	a	range	of	doses	of	two	DNQ	derivatives.	The	efficacy	of	DNQ2	and	
DNQ13	in	killing	tumor	cells	was	assessed	previously(9).	The	DNQ2	formulation	produces	
similar	cytotoxicity	as	the	original	DNQ	and	has	an	IC50	of	.078	±	.024	μM.	However,	DNQ	13,	
which	has	a	bulky	chemical	group	attached	to	its	structure,	is	far	less	efficacious	and	has	an	IC50	
of	6	±	2	μM.	As	displayed	in	Figure	B.3,	these	measures	directly	correlated	to	the	extent	of	
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cytosolic	oxidation	induced	by	their	administration.	When	supplied	at	0.2	μM,	DNQ2	induces	
cytosolic	and	mitochondrial	matrix	oxidation	similar	to	that	of	DNQ,	whereas	no	significant	
oxidation	is	produced	by	DNQ13	when	supplied	at	three	times	that	amount	(0.6	μM)(Figures	
B.3A	and	B).	To	elicit	full	oxidation	of	the	cytosolic	Grx1-roGFP2	biosensor,	less	NQO1-reactive	
DNQ13	had	to	be	administered	at	6uM,	a	concentration	at	which	the	drug	displays	off-target	
thiol-reactivity	with	the	glutathione	biosensor	(Figure	B.3C).	These	results	establish	the	
relationship	between	drug	specificity	for	NQO1	(reported	previously),	cellular	toxicity	(reported	
previously),	and	the	magnitude	of	intracellular	redox	responses	to	drug	administration(9).	
Furthermore,	this	study	demonstrates	the	efficacy	of	employing	redox	biosensors	in	screening	
intracellular	oxidative	responses	to	ROS-producing	chemotherapeutics.		
B.4	Discussion	
The	quinone	chemotherapeutic	DNQ	is	more	NQO1-specific	than	the	similar	quinone	
chemotherapeutic	β-lapachone,	and	thus	it	can	be	used	at	lower	concentrations	to	target	
NQO1-overexpressing	tumor	cells.	Superior	NQO1	specificity	results	in	enhanced	intracellular	
oxidation	in	response	to	drug	administration,	but	DNQ	is	not	completely	immune	from	off-
target	effects,	as	it	induces	an	NQO1-independent	mitochondrial	matrix	oxidation.	Because	
DNQ-induced	mitochondrial	oxidation	is	NQO1-independent,	it	would	likely	affect	transformed	
and	non-transformed	cells	in	a	similar	fashion,	and	thus	it	could	be	a	potential	source	of	side	
effects	in	patients.	Therefore,	future	studies	are	needed	to	uncover	the	mitochondrial	
mechanism	of	this	response.	The	results	presented	herein	demonstrate	that	DNQ	
administration	results	in	a	lasting	alteration	of	mitochondrial	membrane	potential.	Thus,	
prolonged	cellular	exposure	to	DNQ	may	induce	apoptosis	via	mitochondrial	instability.	Similar	
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studies	aimed	at	defining	the	subcellular	cause	of	quinone-based	mitochondrial	oxidation	may	
enable	redesign	of	the	drug	to	limit	non-NQO1-based	off-target	cellular	oxidation.		
The	Grx1-roGFP2	biosensor	was	demonstrated	to	be	an	efficient	tool	for	screening	the	
intracellular	oxidative	responses	induced	by	chemotherapeutic	quinone	administration.	To	the	
best	of	our	knowledge,	this	is	the	first	time	a	roGFP	biosensor	has	been	used	to	screen	redox	
responses	to	unique	chemotherapeutic	formulations.	Because	of	the	biosensor’s	consistency	in	
redox	measurement,	stability	in	genetic	expression	in	cell	culture,	and	amenability	to	plate-
reader	spectrofluorometric	analysis,	this	approach	could	be	used	in	a	high	throughput	fashion	
to	screen	chemotherapeutic	libraries	for	intracellular	redox	activities(18).	However,	a	number	
of	important	considerations	must	be	made	when	using	the	redox	biosensor	in	this	fashion.	First,	
the	drug’s	mechanism	of	action	must	include	hydrogen	peroxide	generation	–	either	directly	or	
following	dismutation	from	superoxide	–	as	the	glutathione	system	must	react	with	hydrogen	
peroxide	via	glutathione	peroxidase	in	order	to	be	recorded	by	the	biosensor.	Thus,	if	the	drug	
were	designed	to	produce	hydroxyl	radical,	for	example,	the	Grx1-roGFP2	biosensor	would	
remain	unaltered	until	that	reactive	oxygen	species	reacted	to	produce	superoxide	or	hydrogen	
peroxide.	Second,	the	biosensor	must	be	examined	in	a	logical	time	frame	suited	to	the	drug’s	
mechanism	of	action.	For	instance,	if	a	chemotherapeutic	agent	is	being	tested	that	inhibits	
antioxidant	enzymes	or	metabolic	pathways	for	redox	preservation,	mechanisms	that	may	take	
many	hours	to	result	in	cellular	oxidation,	the	investigator	must	find	the	proper	end-point	upon	
which	to	assess	cellular	glutathione.	This	is	unlike	the	above	study	of	DNQ,	which	reacts	
immediately	with	NQO1	to	produce	ROS.	Lastly,	as	was	encountered	in	our	study,	chemical	
compounds	that	act	as	intrinsic	oxidants	and	oxidize	the	biosensor	via	direct	interaction	with	
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cellular	thiols	cannot	accurately	be	assessed	for	a	ROS-producing	mechanism	of	action.	Thus,	
investigators	must	be	able	to	confirm	the	drug’s	mechanisms	of	action	via	genetic	or	
pharmacologic	inhibition	and	must	study	time	points	or	concentrations	at	which	the	biosensor	
is	not	reacting	in	this	manner,	as	was	the	case	with	this	study.	With	these	considerations,	the	
Grx1-roGFP2	biosensor	provides	a	unique	capability	to	investigate	distinct	organellar	
glutathione	redox	responses	in	real	time	following	chemotherapeutic	drug	administration.		
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B.5	Figures	
	
	
	
Figure	B.1:	Deoxynyboquine	(DNQ)	redox	cycles	in	the	cytosol	to	produce	superoxide.	A)	
Structure	of	the	quinone	chemotherapeutic	DNQ.	B)	Cytosolic	flavoenzyme	NQO1	attempts	to	
detoxify	DNQ,	but	in	so	doing	forms	unstable	hydroquinone,	which	redox	cycles	in	the	cytosol	
forming	superoxide.	Adapted	from	(9).	
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Figure	B.2:	DNQ	administration	results	in	mitochondrial	membrane	hyperpolarization.	A)	
CCCP-treated	and	untreated	cells	were	stained	with	TMRE	dye	to	assess	mitochondrial	
membrane	potential.	CCCP	serves	as	a	negative	control	to	dissipate	membrane	potential.	B)	
DNQ	induces	mitochondrial	membrane	hyperpolarization.	Representative	bars	are	the	mean	±	
SD	(n	=	3,	P	=	0.05).			
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Figure	B.3:	Grx1-roGFP2	is	an	efficient	tool	for	screening	ROS-producing	chemotherapeutics.	
DNQ-derivatives	induce	probe	oxidation	in	agreement	with	their	potency.	A	and	B)	Biosensor-
expressing	A549	cells	were	exposed	to	0.6μM	DNQ2	(IC50	.06	μM)	and	DNQ13	(IC50	6	μM).	
Redox	plots	of	the	ratio	of	the	395/494	excitation	channels	of	the	Grx1-roGFP2	biosensor	
targeted	to	the	mitochondrial	matrix	(red,	purple;	cells	1,	cell	2)	and	cytosol	(green,	blue;	cell	3,	
cell	4)	display	oxidation	following	DNQ	derivative	administration	(arrow).	C)	Cytosolic	redox	
response	to	administration	of	DNQ	2	and	13	over	a	range	of	concentrations.	Representative	
bars	are	the	mean	±	SEM	(n	≥	5,	P	=	0.05).		
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